Five-year results of atropine 0.01% efficacy in the myopia control in a European population
British Journal of Ophthalmology · 2024
DOI: 10.1136/bjo-2022-322808 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Ophthalmology, 2024. Verfasst von Manuel Moriche-Carretero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infanta Sofia University Hospital, San Sebastian de los Reyes (Madrid), Spain. Hauptthemen laut MEDLINE: Atropine, Mydriatics, Refraction, Ocular, Ophthalmic Solutions. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Aims
To evaluate the efficacy and safety of 0.01% atropine eye-drops in controlling myopia progression over 5 years.
Methods
Experimental, analytical, prospective, randomised and longitudinal study, in 361 right eyes from 361 children randomised into the control group (177 eyes without treatment) and treatment group (184 eyes with 0.01% atropine eye-drops). Children assigned to the treatment group used 0.01% atropine once a day every night and the control group’s children did not use any treatment or placebo. All the subjects completed an eye examination every 6 months for the 5 years of follow-up. The examination included subjective and objective refraction with cycloplegia, axial length (AL), keratometry and anterior chamber depth (ACD) to evaluate the efficacy of the treatment. It also included the anterior and posterior pole examination to evaluate the safety of the treatment.
Results
The SE increased −0.63±0.42D in children after 5 years of treatment with 0.01% atropine, while in the control group the increase was −0.92±0.56D. AL increased 0.26±0.28 mm in the treatment group compared with 0.49±0.34 mm in the control group. Atropine 0.01% showed an efficacy of 31.5% and 46.9% in the control of the SE and AL increase, respectively. ACD and keratometry did not have significant changes between groups.
Conclusions
Atropine 0.01% is effective in slowing myopia progression in a European population. There were no side effects after 5 years of 0.01% atropine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infanta Sofia University Hospital, San Sebastian de los Reyes (Madrid), Spain.
- Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
- Instituto Ocular Europeo, Madrid, Spain.
- ISEC LISBOA - Instituto Superior de Educação e Ciências, Lisboa, Portugal.
- Department of Optometry and Vision, Complutense University of Madrid. Faculty of Optics and Optometry, Madrid, Spain.
- Department of Optometry and Vision, Complutense University of Madrid. Faculty of Optics and Optometry, Madrid, Spain cristina_alvarez@ucm.es.
ORCID-Profile: Miguel Ángel Sánchez-Tena, Cristina Alvarez-Peregrina
Zitieren
APA
Moriche-Carretero, M., Revilla-Amores, R., Gutiérrez-Blanco, A., Moreno-Morillo, F. J., Martinez-Perez, C., Sánchez-Tena, M. Á., & Alvarez-Peregrina, C. (2024). Five-year results of atropine 0.01% efficacy in the myopia control in a European population. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2022-322808
Vancouver
Moriche-Carretero M, Revilla-Amores R, Gutiérrez-Blanco A, Moreno-Morillo FJ, Martinez-Perez C, Sánchez-Tena MÁ, et al. Five-year results of atropine 0.01% efficacy in the myopia control in a European population. British Journal of Ophthalmology. 2024. doi:10.1136/bjo-2022-322808
BibTeX
@article{MoricheCarretero2024,
author = {Moriche-Carretero, Manuel and Revilla-Amores, Remedios and Gutiérrez-Blanco, Ana and Moreno-Morillo, Francisco Javier and Martinez-Perez, Clara and Sánchez-Tena, Miguel Ángel and Alvarez-Peregrina, Cristina},
title = {Five-year results of atropine 0.01% efficacy in the myopia control in a European population},
journal = {British Journal of Ophthalmology},
year = {2024},
doi = {10.1136/bjo-2022-322808}
}
EUVIMED